Cytosorbents Corporation CTSO
4.38
0.08
1.86%
as of 25 Sep
- Market cap
- $13.6M
- P/E
- 0.0×
Follow CTSO
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.03 | 0.05 | 0.05 | 0.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.99) | (1.54) | (0.41) | (1.13) | |
P/B ratio |
0.00 | 0.82 | 0.34 | 0.32 | |
Price to Tangible BV |
0.00 | 0.00 | 0.74 | 0.55 | |
EV/Sales |
0.38 | 0.37 | 0.40 | 0.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.53) | (1.38) | (1.20) | (1.26) | |
EV/FCF |
(1.48) | (1.33) | (1.17) | (1.23) | |
Quick Ratio |
0.47 | 0.73 | 1.42 | 1.48 | |
Current Ratio |
0.66 | 1.09 | 2.13 | 2.11 | |
Net Debt/EBITDA |
(6.48) | (5.11) | (2.78) | (3.10) | |
Debt/Assets |
45.42% | 41.81% | 37.72% | 31.84% | |
Debt/Equity |
(22.96) | 7.73 | 2.82 | 1.62 | |
Asset Turnover |
0.87 | 0.81 | 0.81 | 0.79 | |
Operating CF/Net income |
0.13 | 0.23 | 0.88 | 0.81 | |
Capex/Depreciation |
0.01 | (0.07) | (0.46) | 0.09 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.08% | 11.56% | 13.45% | 9.68% | |
Selling, General and Administrative Expense of Revenue |
82.67% | 91.93% | 102.19% | 90.77% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.07 | 0.00 | |
Share Based Compensation of Revenue |
3.82% | 6.14% | 6.86% | 7.81% | |
Graham Net Nets |
(19.77) | (11.53) | (8.86) | (5.28) | |
Graham Number |
5.59 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1,567.57%) | (666.67%) | (406.25%) | (387.10%) | |
Free Cash Flow Yield |
(810.91%) | (586.51%) | (642.35%) | (347.53%) | |
Revenue per Share |
3.07 | 2.83 | 2.97 | 3.02 | |
Operating CF per Share |
(0.19) | (0.37) | (1.55) | (0.82) | |
Capex per Share |
0.00 | (0.01) | (0.09) | 0.02 | |
Free Cash Flow per Share |
(0.18) | (0.39) | (1.64) | (0.80) | |
Cash per Share |
1.41 | 1.53 | 2.01 | 2.40 | |
Shareholders Equity per Share |
(0.24) | 0.70 | 1.90 | 2.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.24) | 0.70 | 1.90 | 2.87 | |
Free Cash Flow |
(0.58) | (1.21) | (5.12) | (2.52) | |
Working Capital |
(8.29) | 1.45 | 10.93 | 11.20 | |
Capital Expenditures |
0.01 | (0.05) | (0.29) | 0.06 | |
Net Current Asset Value |
(22.97) | (20.61) | (17.64) | (15.42) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.03 | (0.01) | |
Net Profit Margin |
(45.85%) | (57.86%) | (59.52%) | (33.42%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.26 | 7.41 | 7.44 | 7.03 | |
Average Payables |
2.70 | 3.23 | 3.10 | 2.69 | |
Average Inventory |
3.70 | 3.75 | 4.01 | 3.62 | |
Average Assets |
42.98 | 45.67 | 45.78 | 46.78 | |
Average Common Equity |
5.42 | 8.37 | 8.51 | 11.01 |
Columns are period end dates